Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Maintenance Strategies for Patients With mCRC

February 14th 2019

EGFR Therapy in Left-Sided CRC

February 14th 2019

Recommendations for Molecular Testing in mCRC

February 14th 2019

EGFR Therapy for Right-Sided CRC

February 14th 2019

Dr. Eng on the Treatment Landscape in Metastatic Colorectal Cancer

February 13th 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Dr. Lee on Differences Between HIPEC and PIPAC in mCRC

February 9th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.

Microbial Metabolomics: A Search for the Missing Link to Cancer

February 8th 2019

Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.

Surgeon Highlights Regional Therapy Approaches for mCRC

February 8th 2019

Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.

Overcoming Challenges in the Management of mCRC

February 8th 2019

Later-Line Treatment for mCRC: Regorafenib or TAS-102?

February 8th 2019

mCRC: Stratifying Patients to Appropriate Therapy

February 8th 2019

Improving Molecular Understandings of mCRC

February 8th 2019

Metastatic Colorectal Cancer: Frontline Treatment Paradigm

February 8th 2019

Future of CRC Rests in Greater Genomic Understanding

February 7th 2019

Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.

Dr. Kasi on the Application of Pharmacogenomics in CRC

February 5th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Online Tool Estimates the Risk for Lynch Syndrome

February 5th 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Expert Discusses CRC Developments, Importance of Molecular Profiling

February 4th 2019

Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

January 31st 2019

First-Line Triplet in BRAF+ mCRC

January 31st 2019

Real-World Management of Patients with BRAF-V600E mCRC

January 31st 2019